PRECIGEN, INC.(PGEN)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
PRECIGEN, INC. (PGEN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PGEN at 29.6/100 on a 32-signal composite quality model, placing it at rank #2,526 of 2,960 stocks — the bottom half of the AI-ranked universe. PGEN scores in the top quartile across revenue growth (98.1). Areas of concern include balance sheet strength (0.9) and profitability (5.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PRECIGEN, INC. reports quarterly revenue of $55.0M, net income of $20.1M, free cash flow of $-18.2M. Top institutional holders of PGEN by reported 13-F value include Patient Capital Management, BlackRock, STATE STREET, based on the most recent SEC filings. PGEN trades on the Nasdaq exchange and files with the SEC under CIK 1356090. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PGEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PRECIGEN, INC. directly from SEC EDGAR.
AI Quality Score
29.6/100
AI Rank
#2,526
Revenue
$55.0M
Net Income
$20.1M
Free Cash Flow
$-18.2M
PGEN key financials by period
PRECIGEN, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$9.7M
$-250.6M
—
FY 2024
10-K
$3.9M
$-126.2M
—
FY 2023
10-K
$6.2M
$-95.9M
—
FY 2022
10-K
$26.9M
$28.3M
—
FY 2021
10-K
$14.3M
$-92.2M
—
FY 2020
10-K
$32.0M
$-170.5M
—
Institutions holding PGEN
Institutional investors reporting a position in PRECIGEN, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Precigen achieved $55.0M in Q2 2026 revenue, driven by $53.1M from Papzimeos commercial sales following FDA approval, swinging to $20.1M net income from $26.6M loss in prior year.
Biggest Revenue Drivers
Papzimeos product revenue$53.1MFirst quarter of sales post-FDA approval
FDA-approved immunotherapy for recurrent respiratory papillomatosis launched in August 2025; sales commenced Q4 2025.
Biggest Revenue Drivers
Papzimeos product revenue$53.1MFirst quarter of sales post-FDA approval
FDA-approved immunotherapy for recurrent respiratory papillomatosis launched in August 2025; sales commenced Q4 2025.
Largest Expense Items
Selling, general and administrative$22.2M+38% YoY
Increased commercialization costs, marketing, promotional activities, and personnel costs to support Papzimeos launch
Research and development$7.3M-37% YoY
Decrease due to Papzimeos manufacturing costs now capitalized as inventory post-FDA approval rather than expensed as R&D
Cost of products and services$2.8M+157% YoY
Increase reflects commercial Papzimeos manufacturing and distribution costs; approximately $1.1M related to Exemplar operations
Margins: Gross margin on Papzimeos sales benefited from pre-launch inventory with favorable per-unit costs; company expects margins to stabilize in high 80s to low 90s percentage range as pre-launch inventory is sold through Q3 2026. Operating margin improved sharply due to revenue contribution from approved product.
Watch Items from the Filing
Customer payment terms of 127 days on Papzimeos drove accounts receivable to $71.9M from $3.9M YoY, representing significant working capital requirement and collection risk.
Pre-launch Papzimeos inventory of ~$20.2M expected to generate ~$9M in future revenues; company expects to sell all pre-launch inventory by Q3 2026, creating timing risk for revenue recognition.
$93.9M long-term debt maturing September 2030 with variable SOFR-based interest rate (6.5% margin, 3.75% floor); quarterly principal payments begin December 2028. Each 100 bps SOFR increase adds ~$1M annual interest expense.
Company achieved first operating profitability ($20.1M net income Q2 2026) but remains dependent on Papzimeos commercialization success; accumulated deficit of $2.3B as of June 30, 2026.
Clinical pipeline advancement paused for PRGN-3005 and PRGN-3007 programs per August 2024 strategic prioritization; PRGN-3006 enrollment complete, seeking partnership opportunities for advancement.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
